Trajan Scientific and Medical

Global Corporate Headquarters
7 Argent Place, Ringwood
Victoria 3134, Australia
Tel: +61 (0) 3 9837 4200
www.trajanscimed.com

Trajan Group Holdings Limited
ACN 152 617 706

ASX RELEASE

2026 Annual General Meeting Chair Address and Presentation

28 October 2026 – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan** or **the Company**) advises, in accordance with Listing Rule 3.13.3, a copy of the address by the Chairman Mr John Eales and slides to be presented at today's Annual General Meeting are attached.

Authorised for ASX release by the Board of Trajan Group Holdings Limited.

END

Contact:

Investors
investorrelations@trajanscimed.com

Media
media@trajanscimed.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of approximately 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.

Chair's Address

Ladies and gentlemen, fellow shareholders, thank you for joining us today. It is a privilege to welcome you to Trajan's Annual General Meeting.

FY26 was a challenging year for global businesses, including Trajan. In the first quarter we encountered the initial impact of US tariffs and, whilst our decision to rapidly invest in "in-region, for-region" capability was warranted, it added implementation costs. Additional pressure was felt as we experienced significant softness in our Capital Equipment business. In the second quarter, the trajectory shifted, with business gaining momentum and realising more cost benefits from project Neptune.

From February the business was confronted with a step change in foreign exchange rates which had a direct impact on the reported financial result. On a constant currency basis, however, the business largely executed to plan in H2 carrying solid momentum into FY27.

For the full year, revenue was $161.4 million and normalised EBITDA was $13.2 million, both down on the prior year with the FX impact in H2 suppressing revenue by $5M and nEBITDA by $2.4M.

For me, what matters when reflecting on FY26 is how well the business responded to adversity. From the second quarter onward, performance improved. Despite the currency headwind, the second half was stronger than the first, with improved margins and a more efficient cost base. Headcount was reduced from approximately 645 full-time employees in September to fewer than 600 as FY27 commenced.

Trajan is a business with real capability. It is diversified across products, customers, geographies and end markets. Our Components and Consumables segment, which remains the core of the group, was stable throughout the year and continues to provide a strong foundation. Disruptive Technologies progressed further, particularly in microsampling. Capital Equipment faced more difficult market conditions, but it finished the year with a stronger order book and improving margins.

That balance matters. It gives Trajan resilience. It means we are not relying on one product, one market, or one region to carry the business.

Trajan also has a genuine competitive advantage in its multi-site organisation. Our footprint across Australia, the US, Europe and Asia gives us flexibility, customer proximity and supply chain resilience that matter all the more in uncertain markets. It supports our "in-region, for-region" model and strengthens our ability to respond as conditions change.

We also continued to strengthen the business operationally. Through Project Neptune and other initiatives, management has been building a simpler, more efficient and more scalable organisation. That included reducing overheads, rationalising parts of our footprint, advancing our multi-site manufacturing model, and completing an important phase of the global ERP rollout.

And throughout the year, we continued to execute against our strategic plan: growing globally, moving further up the value chain, improving margins, and using our footprint to manage risk and support long-term growth.

What has not changed is Trajan's purpose. "Science that benefits people" remains the test we apply to everything we do. Our products help customers improve the quality and reliability of analysis across clinical, pharmaceutical, food and environmental applications. That gives the business both relevance and direction.

The Board understands that shareholders expect more than long-term potential. They expect discipline, performance and clear communication. And they rightly want to see the underlying quality of the business

better reflected over time. Like you, we have been disappointed by the share price. But our response is to stay focused on the fundamentals; building a better business, improving returns, and making sure the market has a clearer understanding of the value being created.

As we move into FY27, there are encouraging signs both internally and from the market. The improvement throughout the second half of FY26, the work done on margins and costs, the strength of our multi-site operating model, and the breadth of the portfolio give us a sound base for the year ahead.

That does not mean we should get ahead of ourselves. Conditions remain mixed in some areas, and execution will continue to matter. But the fundamentals of the business are sound, and Trajan is in good shape to keep moving forward.

At the conclusion of this address, our CEO, Mr Stephen Tomisich, will provide a business update and speak to the priorities ahead.

Before I finish, I would like to thank Stephen, Simon, the executive team, our people around the world, and my fellow directors for their work through what was a demanding year. And to our shareholders, thank you for your continued support.

You place your trust in us to build lasting value. FY26 was a testing year, but Trajan remains a resilient business with strong capabilities, a clear purpose, a competitive operating model, and a solid foundation. We remain focused on doing the work well, executing our strategy, improving performance, and building value over the long term.

Thank you.

TRAJAN | Science that benefits people



2026 Annual General Meeting

Wednesday, 28 October 2026

YOUR BOARD



John Eales AM

Non-Executive Chair



Stephen Tomisich

Founder, CEO and Executive Director



Robert Lyon

Executive Director



Tiffiny Lewin

Non-Executive Director




Dr Rohit Khanna

Non-Executive Director

QUESTION PROCESS

HOW TO ASK A QUESTION


- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send button
- To ask a verbal question follow the instructions below the broadcast window



VOTING PROCESS

HOW TO VOTE

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



Address by the Chairman

Mr John Eales, AM



CEO’s Presentation

Mr Stephen Tomisich



TRAJAN | Science that benefits people



CEO Update

Stephen Tomisich, CEO and Managing Director

28 October 2026

Disclaimer

The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 28 October 2026. The information in the presentation is provided for information purposes only, is in summary form and does not purport to be complete. It should be read in conjunction with Trajan's other announcements to the ASX, including the FY26 Annual Report, Results announcement, and Appendix 4D. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor, taxation situation or needs of any particular investor. A shareholder, investor or potential investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Trajan and conduct its own investigations and analysis. No representation is made as to the accuracy, completeness or reliability of the presentation. Trajan is not obliged to, and does not represent that it will, update the presentation for future developments.

All currency figures are in Australian dollars unless otherwise stated. Totals and change calculations may not equate precisely due to rounding.

This presentation contains statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believe", "estimate", "plan", "target", "project", "anticipate", "expect", "intend", "likely", "may", "will", "could" or "should" or similar expressions, or by discussions of strategy, plans, objectives, targets, goals, future events or intentions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. You are cautioned not to place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Trajan or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Past performance is also not indicative of future performance, and no guarantee of future returns is implied or given. Nothing contained in this presentation is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of Trajan.

By reading this presentation you agree to be bound by the limitations set out in this disclaimer. No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this presentation. To the maximum extent permitted by law, neither Trajan nor any of its related entities, or their respective directors, employees or agents, nor any other person accepts liability for loss arising from the use of or reliance on information contained in this presentation or otherwise arising in connection with it, including without limitation any liability from fault of negligence.

FY2026 Financial Summary

REVENUE & EARNINGS

Group Revenue [PCP: $166.5M] — **$161.4M** Down 3.1%

Group nEBITDA [PCP: $15.5M] — **$13.2M** Down 14.7%

Proforma Gross Margin [PCP: 39.8%] — **38.9%** Down 0.8pts


Operating NPATA [PCP:$0.8M] — **$2.2M** Up 191.3%

FINANCIAL POSITION

Cash [PCP $11.9M] — **$12.6M** Up 6.5%

Net Debt [PCP: $29.5M] — **$34.6M** Up17.0%

FOREX FY2026 AUD:USD and EUR



KEY POINTS

- **Revenue:** Reported revenue declined due to forex volatility. Underlying H2 FY26 revenue was impacted by circa $5.0M due to AUD appreciation.
- **nEBITDA:** H2 FY26 nEBITDA increased to $8.1M, up 61.8% from H1 FY26 $5.0M, driven by the realisation of cost efficiency measures. With group H2 nEBITDA rising to $10.5M on a fixed currency basis (AUD adjusted to H1 Forex rates).
- **Proforma Gross Margin:** Reported margin declined during H1. In H2 FY26 it increased to 40.6% (+3.2 pts vs H1), and 41.2% in H2 at H1 Forex rates.
- **NPATA**: Growth of NPATA reflects improved underlying profitability and disciplined cost management, particularly in H2.
- **AUD appreciation**: Sustained appreciation in H2 FY26. Approximately 85% of Trajan revenues derived in USD and EUR.

1. Operating Net Profit After Tax plus Amortisation (NPATA) is Statutory NPAT excluding restructuring costs, acquisition costs, impact from FECs revaluation, amortisation of acquired intangible assets.
2. nEBITDA is statutory EBITDA excluding restructuring costs, acquisition costs and impact from FECs revaluation.

FY27 begins with promising momentum

FY27 Q1 Update

Management accounts* indicate:

- nEBITDA momentum has continued with a result of circa $3.5M in the quarter, taking the rolling 12-month nEBITDA to $16.2M

- Net revenue** is up 3.8% compared to FY26 Q1 with:
  - Components & Consumables up by 5.2%
  - Disruptive Technologies up by 12.7%
  - Capital Equipment, still challenged though, down by 1.2%

- Net Debt reduced in Q1 by $1.6M

(*Unaudited FY27 Q1 financial results)
(** Fixed forex rates used for net revenue comparison)




Operational Improvement Continues

As this stage of Project Neptune gains traction, the business becomes leaner and it starts to deliver the intended impact:

- Gross Margin, FY27 Q1 proforma %GP above 42%, up 15% on Q1 prior year.
- Employee Expense, down 8%+ on Q1 prior year.
- Scrap, down 8%+
- Project Neptune continues to drive efficiencies going forward.

(unaudited FY27 Q1 financial results)




(Source: Trajan Sharewise Webinar 08 Oct 2026)

Resilience in Components & Consumables

Trajan's largest Business Segment

Annualised revenue, at monthly resolution and fixed forex rates, reveals that post destocking (March 2024), growth rate is back to normal.





Caution remains about short-term Capital Equipment outlook

Confidence in the long-term potential, but still rough waters at present

Capital Equipment revenues were mostly flat in Q1, and that is against a relatively weak Q1 in the prior year.

The opportunity funnel, both food and pharma related, remains healthy, with several new products scheduled for launch in FY27.



Science that benefits people, here's what our customers say:

Drug discovery for Malaria

The University of Dundee's Drug Discovery Unit used **Trajan's HDX and HDExaminer software** to develop a new way to measure drug–target affinity applied to a malaria parasite target; the method gave complete coverage of the protein and binding strengths across more than 50 regions.

Food contamination

"*Our long-standing partnership with **Trajan** has played an important role in developing our MOSH MOAH expertise. Based on **CHRONECT MOxH solutions**, **reliable service**, and a **continuous exchange of technical expertise**, our collaboration has grown into a trusted and valuable partnership."*

Research performance

*"Some of our samples represent critical research into human health and disease. When samples are irreplaceable, we need consumables we can trust. That's why we choose **Trajan syringes** for their robustness and accuracy."*

Treatment monitoring for Epilepsy

IRCCS (Bologna, Italy) published a real-world evaluation of **Trajan's VAMS® sampling technology** for monitoring of anti-seizure medications. Of 105 people with epilepsy; at-home results showed strong correlation (Pearson's r ranging from 0.88 - 0.98) compared to in clinic collection.

"*Patients reported VAMS self-collection as feasible, easy, and well-tolerated.*"

Breast cancer diagnostics

"*We used to have so many issues with specimens floating off our previous slides. We switched to the **Trajan Series 2 adhesive slides** and now have hardly any repeats. We love the **Trajan** slides.*"

Environmental analysis

***"Trajan's HT8 PCB column** is the only column that I can rely on for my POPs analysis. When these columns become scarce, I ask my contacts to find any available column to keep in stock, as I cannot afford to be without one to run our samples."*

And that's just from management reports in one month - Aug 2026!


FY27 Guidance

Based on the current trajectory and AUD exchange rates we expect in FY27 to achieve:

- **Net Revenue $162M - $166M.**
- **nEBITDA $16.0M – $17.5M.**

The mid-point of the revenue projection assumes current FX rates and continued softness in Capital Equipment, hence the 2% implied growth at actual rates.

The mid-point of the nEBITDA projection represents a 27% uplift over FY26 as the business continues to expand margins and address cost structures through project Neptune.





Business of the Meeting

Item 1

Financial Statements and Reports

The first item of business is to receive and consider the Company's Annual Financial Report, including the Directors' Report and Audit Report for the year ended 30 June 2026.

Note: There is no vote required for this item.

Resolution 1

Adoption of Remuneration Report

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That, for the purposes of Section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report as contained in the Directors' Report for the year ended 30 June 2026, be adopted."

Note: The vote on this resolution is advisory only and does not bind the Directors or the Company.

Proxy Voting Results - Resolution 1

Adoption of Remuneration Report

	Number	%[2]
For	35,235,784	98.99
Against	298,220	0.84
Open – Chair[1]	50,450	0.14
Other	12,000	0.03
Abstain/Exclude	79,862,981	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Resolution 2

Re-election of Mr John Eales as a Director

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That, John Eales, who retires in accordance with clause 12.5 of the Company's Constitution and ASX Listing Rule 14.4 and, being eligible, offers himself for re-election, be re-elected as a Director of the Company."

Proxy Voting Results - Resolution 2

Re-election of Mr John Eales as a Director

	Number	%[2]
For	112,978,950	99.08
Against	995,145	0.87
Open – Chair[1]	50,450	0.04
Other	12,000	0.01
Abstain/Exclude	1,422,890	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Resolution 3

Re-election of Ms Tiffiny Lewin as a Director

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That, Tiffiny Lewin, who retires in accordance with clause 12.5 of the Company's Constitution and ASX Listing Rule 14.4 and, being eligible, offers herself for re-election, be re-elected as a Director of the Company."

Proxy Voting Results - Resolution 3

Re-election of Ms Tiffiny Lewin as a Director

	Number	%[2]
For	114,481,214	99.16
Against	915,145	0.79
Open – Chair[1]	50,450	0.04
Other	12,000	0.01
Abstain/Exclude	626	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Resolution 4

Grant of Options to Director - Mr John Eales

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That, subject to the passing of Resolution 2, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 292,683 Options to Mr John Eales (or his nominee), under the Plan on the basis set out in the Explanatory Memorandum."

Proxy Voting Results - Resolution 4

Grant of Options to Director - Mr John Eales

	Number	%[2]
For	35,136,286	96.86
Against	1,116,069	3.08
Open – Chair[1]	11,250	0.03
Other	12,000	0.03
Abstain/Exclude	79,183,830	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Resolution 5

Grant of Options to Director - Dr Rohit Khanna

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

''That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 195,122 Options to Dr Rohit Khanna (or his nominee), under the Plan on the basis set out in the Explanatory Memorandum."

Proxy Voting Results - Resolution 5

Grant of Options to Director - Dr Rohit Khanna

	Number	%[2]
For	35,142,786	96.88
Against	1,116,069	3.08
Open – Chair[1]	4,750	0.01
Other	12,000	0.03
Abstain/Exclude	79,183,830	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Resolution 6

Grant of Options to Director - Ms Tiffiny Lewin

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That, subject to the passing of Resolution 3, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 195,122 Options to Ms Tiffiny Lewin (or her nominee), under the Plan on the basis set out in the Explanatory Memorandum."

Proxy Voting Results - Resolution 6

Grant of Options to Director - Ms Tiffiny Lewin

	Number	%[2]
For	35,136,286	96.88
Against	1,116,069	3.08
Open – Chair[1]	4,750	0.01
Other	12,000	0.03
Abstain/Exclude	79,190,330	N/A

[1] To be voted in favour of the resolution

[2] Of proxies cast

Questions

Voting and Meeting Close

Thank you.

If you have not yet voted, please proceed with voting now.

The final results of the meeting will be advised to the ASX and will be available on Trajan's investor website after the meeting.

Thank you for your attendance.

Thank you